These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 28871)

  • 1. Effects of aging and liver disease on disposition of lorazepam.
    Kraus JW; Desmond PV; Marshall JP; Johnson RF; Schenker S; Wilkinson GR
    Clin Pharmacol Ther; 1978 Oct; 24(4):411-9. PubMed ID: 28871
    [No Abstract]   [Full Text] [Related]  

  • 2. The effects of liver disease and aging on the disposition of diazepam, chlordiazepoxide, oxazepam and lorazepam in man.
    Wilkinson GR
    Acta Psychiatr Scand Suppl; 1978; (274):56-74. PubMed ID: 32740
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of liver disease and of aging on the disposition and elimination of sedatives.
    Schenker S
    Trans Am Clin Climatol Assoc; 1978; 89():91-9. PubMed ID: 30206
    [No Abstract]   [Full Text] [Related]  

  • 4. Disposition and elimination of minor tranquilizers in the aged and in patients with liver disease.
    Hoyumpa AM
    South Med J; 1978 Aug; 71 Suppl 2():23-8. PubMed ID: 28572
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical pharmacokinetics of oxazepam and lorazepam.
    Greenblatt DJ
    Clin Pharmacokinet; 1981; 6(2):89-105. PubMed ID: 6111408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic and extrahepatic glucuronidation of lorazepam in the dog.
    Gerkens JF; Desmond PV; Schenker S; Branch RA
    Hepatology; 1981; 1(4):329-35. PubMed ID: 6116660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of uremia and hemodialysis on lormetazepam disposition.
    Kampf D; Huempel M; Lerche U; Kessel M
    Clin Pharmacol Ther; 1981 Jul; 30(1):77-85. PubMed ID: 6113073
    [No Abstract]   [Full Text] [Related]  

  • 8. [Effect of various types of liver diseases on the behavior of cefoperazone].
    Malè PJ; Dayer P; Châtelain G; Rudhardt M; Fabre J
    Schweiz Med Wochenschr; 1983 Dec; 113(49):1860-3. PubMed ID: 6676938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition pharmacokinetics of lorazepam in the rabbit.
    Nielsen-Kudsk F; Jakobsen P
    Acta Pharmacol Toxicol (Copenh); 1980 May; 46(5):388-91. PubMed ID: 6103631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lorazepam kinetics in the elderly.
    Greenblatt DJ; Allen MD; Locniskar A; Harmatz JS; Shader RI
    Clin Pharmacol Ther; 1979 Jul; 26(1):103-13. PubMed ID: 36252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics of oxazepam and lorazepam in two subjects with Gilbert syndrome.
    Shader RI; Divoll M; Greenblatt DJ
    J Clin Psychopharmacol; 1981 Nov; 1(6):400-2. PubMed ID: 6120963
    [No Abstract]   [Full Text] [Related]  

  • 12. Disposition and metabolism of lorazepam in the male rat.
    Schillings RT; Sisenwine SF; Ruelius HW
    Drug Metab Dispos; 1977; 5(5):425-35. PubMed ID: 20290
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical pharmacokinetics of lorazepam. I. Absorption and disposition of oral 14C-lorazepam.
    Greenblatt DJ; Schillings RT; Kyriakopoulos AA; Shader RI; Sisenwine SF; Knowles JA; Ruelius HW
    Clin Pharmacol Ther; 1976 Sep; 20(3):329-41. PubMed ID: 8232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans.
    Greenblatt DJ; Shader RI; Franke K; MacLaughlin DS; Harmatz JS; Allen MD; Werner A; Woo E
    J Pharm Sci; 1979 Jan; 68(1):57-63. PubMed ID: 31453
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of age and cardiopulmonary bypass on the pharmacokinetics of lorazepam.
    Aaltonen L; Kanto J; Arola M; Iisalo E; Pakkanen A
    Acta Pharmacol Toxicol (Copenh); 1982 Aug; 51(2):126-31. PubMed ID: 6126064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cimetidine spares the glucuronidation of lorazepam and oxazepam.
    Patwardhan RV; Yarborough GW; Desmond PV; Johnson RF; Schenker S; Speeg KV
    Gastroenterology; 1980 Nov; 79(5 Pt 1):912-6. PubMed ID: 6106621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired elimination of lorazepam following subchronic administration in two patients with renal failure.
    Verbeeck RK; Tjandramaga TB; De Schepper PJ; Verberckmoes R
    Br J Clin Pharmacol; 1981 Nov; 12(5):749-51. PubMed ID: 6120712
    [No Abstract]   [Full Text] [Related]  

  • 18. Significance of plasma glutathione determination in patients with alcoholic and non-alcoholic liver disease.
    Shigesawa T; Sato C; Marumo F
    J Gastroenterol Hepatol; 1992; 7(1):7-11. PubMed ID: 1543872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacokinetics of lorazepam. III. Intravenous injection. Preliminary results.
    Greenblatt DJ; Comer WH; Elliott HW; Shader RI; Knowles JA; Ruelius HW
    J Clin Pharmacol; 1977; 17(8-9):490-4. PubMed ID: 19508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The liver and circulating thyroid hormones.
    Klachko DM; Johnson ER
    J Clin Gastroenterol; 1983 Oct; 5(5):465-71. PubMed ID: 6313798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.